drug
ACTEMRA
updated 6mo agoby Genentech Inc
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval264 co-mentions · 72 sources
- drugtocilizumab253 co-mentions · 73 sources
- drugTYENNE16 co-mentions · 8 sources
- drugRNS-608 co-mentions · 8 sources
- companyFresenius Kabi USA LLC8 co-mentions · 8 sources
- drugAVTOZMA8 co-mentions · 4 sources
- companyCelltrion Inc4 co-mentions · 4 sources
- companyChugai Pharmaceutical Co Ltd1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying ACTEMRA
- phase3A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig
- phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
- phase1A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- phase2A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- phase2A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
- phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- phase1A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- phase1A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
News(3)
- Roche sets sights on FDA approval decision of July 2027 with updated eye drug dataOne year on from a mixed phase 3 readout, Roche has shared updated data from eye disease trials that could support FDA approval by July.fiercebiotech · 1mo ago
- Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass ParticlesFOR IMMEDIATE RELEASE – August 10, 2026 – LAKE ZURICH, Ill.— Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (…fda_medwatch · 3mo ago
- Dr Silbermann on Clinical Trial Design Considerations in Multiple MyelomaRebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.onclive · 6mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that